Katja Pinker

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3699230/publications.pdf

Version: 2024-02-01

228 papers 9,672 citations

57
h-index

85 g-index

246 all docs

246 docs citations

246 times ranked

8064 citing authors

#	Article	IF	CITATIONS
1	Editorial for "TP53 Mutation Estimation Based on Radiomics Analysis for Breast Cancerâ€. Journal of Magnetic Resonance Imaging, 2023, 57, 1104-1105.	3.4	O
2	Magnetic resonance imaging before breast cancer surgery: results of an observational multicenter international prospective analysisÂ(MIPA). European Radiology, 2022, 32, 1611-1623.	4. 5	30
3	Radiologist-Level Performance by Using Deep Learning for Segmentation of Breast Cancers on MRI Scans. Radiology: Artificial Intelligence, 2022, 4, e200231.	5 . 8	16
4	Differentiation Between Benign and Metastatic Breast Lymph Nodes Using Apparent Diffusion Coefficients. Frontiers in Oncology, 2022, 12, 795265.	2.8	8
5	Breast <scp>MRI</scp> Background Parenchymal Enhancement Categorization Using Deep Learning: Outperforming the Radiologist. Journal of Magnetic Resonance Imaging, 2022, 56, 1068-1076.	3.4	9
6	Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI). European Radiology, 2022, 32, 4036-4045.	4.5	137
7	MRI Screening of <i>BRCA</i> Mutation Carriers: Comparison of Standard Protocol and Abbreviated Protocols With and Without T2-Weighted Images. American Journal of Roentgenology, 2022, 218, 810-820.	2.2	11
8	Multiparametric 18F-FDG PET/MRI-Based Radiomics for Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Cancers, 2022, 14, 1727.	3.7	20
9	Editorial: Impact of Breast MRI on Breast Cancer Treatment and Prognosis. Frontiers in Oncology, 2022, 12, 825101.	2.8	1
10	Breast Lesion Classification with Multiparametric Breast MRI Using Radiomics and Machine Learning: A Comparison with Radiologists' Performance. Cancers, 2022, 14, 1743.	3.7	16
11	Editorial for " <scp>Breast Tissue Chemistry Measured</scp> In Vivo in Healthy <scp>Women Correlate With Breast Density</scp> and <scp>Breast Cancer Risk</scp> ― Journal of Magnetic Resonance Imaging, 2022, 56, 1370-1371.	3.4	0
12	A survey by the European Society of Breast Imaging on the implementation of breast diffusion-weighted imaging in clinical practice. European Radiology, 2022, 32, 6588-6597.	4. 5	14
13	Combining the strengths of radiologists and Al for breast cancer screening: a retrospective analysis. The Lancet Digital Health, 2022, 4, e507-e519.	12.3	79
14	Diagnostic value of diffusion-weighted imaging with synthetic b-values in breast tumors: comparison with dynamic contrast-enhanced and multiparametric MRI. European Radiology, 2021, 31, 356-367.	4.5	28
15	Can Follow-up be Avoided for Probably Benign US Masses with No Enhancement on MRI?. European Radiology, 2021, 31, 975-982.	4.5	3
16	Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade. Breast Cancer Research and Treatment, 2021, 187, 535-545.	2.5	13
17	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	10.7	49
18	Multispectral Imaging for Metallic Biopsy Marker Detection During MRI-Guided Breast Biopsy: A Feasibility Study for Clinical Translation. Frontiers in Oncology, 2021, 11, 605014.	2.8	0

#	Article	lF	Citations
19	Multidimensional Diffusion Magnetic Resonance Imaging for Characterization of Tissue Microstructure in Breast Cancer Patients: A Prospective Pilot Study. Cancers, 2021, 13, 1606.	3.7	20
20	An A.I. classifier derived from 4D radiomics of dynamic contrast-enhanced breast MRI data: potential to avoid unnecessary breast biopsies. European Radiology, 2021, 31, 5866-5876.	4.5	18
21	Breast Tumor Characterization Using [18F]FDG-PET/CT Imaging Combined with Data Preprocessing and Radiomics. Cancers, 2021, 13, 1249.	3.7	32
22	Fat Composition Measured by Proton Spectroscopy: A Breast Cancer Tumor Marker?. Diagnostics, 2021, 11, 564.	2.6	6
23	High-risk lesions of the breast: concurrent diagnostic tools and management recommendations. Insights Into Imaging, 2021, 12, 63.	3.4	37
24	Radiomics and Machine Learning with Multiparametric Breast MRI for Improved Diagnostic Accuracy in Breast Cancer Diagnosis. Diagnostics, 2021, 11, 919.	2.6	25
25	Multiparametric Integrated 18F-FDG PET/MRI-Based Radiomics for Breast Cancer Phenotyping and Tumor Decoding. Cancers, 2021, 13, 2928.	3.7	34
26	Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI). Insights Into Imaging, 2021, 12, 119.	3.4	51
27	Al-enhanced breast imaging: Where are we and where are we heading?. European Journal of Radiology, 2021, 142, 109882.	2.6	35
28	Diffusion-weighted Imaging Allows for Downgrading MR BI-RADS 4 Lesions in Contrast-enhanced MRI of the Breast to Avoid Unnecessary Biopsy. Clinical Cancer Research, 2021, 27, 1941-1948.	7.0	51
29	Using Deep Learning to Improve Nonsystematic Viewing of Breast Cancer on MRI. Journal of Breast Imaging, 2021, 3, 201-207.	1.3	12
30	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers, 2021, 13, 6273.	3.7	9
31	Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes. Molecular Imaging and Biology, 2020, 22, 453-461.	2.6	57
32	Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist, 2020, 25, e231-e242.	3.7	96
33	Multiparametric 18F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer?. Journal of Nuclear Medicine, 2020, 61, 20-25.	5.0	12
34	Contrast-Enhanced Mammography and Radiomics Analysis for Noninvasive Breast Cancer Characterization: Initial Results. Molecular Imaging and Biology, 2020, 22, 780-787.	2.6	53
35	Machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy. Breast, 2020, 49, 115-122.	2.2	52
36	Diffusion-weighted imaging of the breastâ€"a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. European Radiology, 2020, 30, 1436-1450.	4.5	255

#	Article	IF	CITATIONS
37	MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer. EBioMedicine, 2020, 61, 103042.	6.1	68
38	Contrast-Enhanced Mammography for Screening Women after Breast Conserving Surgery. Cancers, 2020, 12, 3495.	3.7	16
39	Radiomics for Tumor Characterization in Breast Cancer Patients: A Feasibility Study Comparing Contrast-Enhanced Mammography and Magnetic Resonance Imaging. Diagnostics, 2020, 10, 492.	2.6	29
40	Non-Invasive Assessment of Hypoxia and Neovascularization with MRI for Identification of Aggressive Breast Cancer. Cancers, 2020, 12, 2024.	3.7	9
41	Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. JAMA Network Open, 2020, 3, e2018790.	5.9	10
42	AI â€Enhanced Diagnosis of Challenging Lesions in Breast MRI : A Methodology and Application Primer. Journal of Magnetic Resonance Imaging, 2020, 54, 686-702.	3.4	26
43	Current Status and Future Perspectives of Artificial Intelligence in Magnetic Resonance Breast Imaging. Contrast Media and Molecular Imaging, 2020, 2020, 1-18.	0.8	16
44	MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival. Breast Cancer Research, 2020, 22, 93.	5.0	4
45	Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging at 7T for Breast Cancer Diagnosis and Characterization. Cancers, 2020, 12, 3763.	3.7	3
46	Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 545-555.	2.8	5
47	A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy. Breast Cancer Research, 2020, 22, 57.	5.0	63
48	Non-Invasive Assessment of Breast Cancer Molecular Subtypes with Multiparametric Magnetic Resonance Imaging Radiomics. Journal of Clinical Medicine, 2020, 9, 1853.	2.4	57
49	High-Spatial-Resolution Multishot Multiplexed Sensitivity-encoding Diffusion-weighted Imaging for Improved Quality of Breast Images and Differentiation of Breast Lesions: A Feasibility Study. Radiology Imaging Cancer, 2020, 2, e190076.	1.6	19
50	Combining molecular and imaging metrics in cancer: radiogenomics. Insights Into Imaging, 2020, 11, 1.	3.4	150
51	Preoperative MRI Improves Surgical Planning and Outcomes for Ductal Carcinoma in Situ. Radiology, 2020, 295, 304-306.	7.3	11
52	Mammographic Breast Density and Urbanization: Interactions with BMI, Environmental, Lifestyle, and Other Patient Factors. Diagnostics, 2020, 10, 418.	2.6	2
53	A rapid volume of interest-based approach of radiomics analysis of breast MRI for tumor decoding and phenotyping of breast cancer. PLoS ONE, 2020, 15, e0234871.	2.5	33
54	Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers. European Radiology, 2020, 30, 6721-6731.	4.5	31

#	Article	IF	Citations
55	Clinical relevance of total choline (tCho) quantification in suspicious lesions on multiparametric breast MRI. European Radiology, 2020, 30, 3371-3382.	4.5	12
56	Elevated glycine detected on in vivo magnetic resonance spectroscopy in a breast cancer patient: case report and literature review. BJR case Reports, 2020, 6, 20190090.	0.2	2
57	Can second-look ultrasound downgrade MRI-detected lesions? A retrospective study. European Journal of Radiology, 2020, 127, 108976.	2.6	5
58	Image-guided breast biopsy and localisation: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Into Imaging, 2020, 11, 12.	3.4	96
59	Transmission of vector vortex beams in dispersive media. Advanced Photonics, 2020, 2, 1.	11.8	52
60	Propagation of structured light through tissue-mimicking phantoms. Optics Express, 2020, 28, 35427.	3.4	8
61	and Phenotype Presentation of Breast Cancer with a Special Focus on High-Risk Women., 2020, , 113-130.		0
62	Is Background Parenchymal Enhancement an Important Risk Factor for Breast Cancer Development in Women with Increased Risk?. Radiology, 2019, 292, 562-563.	7.3	3
63	Mammographic screening in male patients at high risk for breast cancer: is it worth it?. Breast Cancer Research and Treatment, 2019, 177, 705-711.	2.5	18
64	Diffusion-weighted MRI for Unenhanced Breast Cancer Screening. Radiology, 2019, 293, 504-520.	7.3	92
65	Clinical applications of breast cancer metabolomics using high-resolution magic angle spinning proton magnetic resonance spectroscopy (HRMAS 1H MRS): systematic scoping review. Metabolomics, 2019, 15, 148.	3.0	8
66	Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response – A Prospective Study. Scientific Reports, 2019, 9, 16372.	3.3	44
67	Automatic segmentation and classification of breast lesions through identification of informative multiparametric PET/MRI features. European Radiology Experimental, 2019, 3, 18.	3.4	25
68	Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results. Breast Cancer Research, 2019, 21, 106.	5.0	81
69	PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2â [*] Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT. Molecular Imaging and Biology, 2019, 21, 991-1002.	2.6	8
70	Multimodality Imaging of Breast Parenchymal Density and Correlation with Risk Assessment. Current Breast Cancer Reports, 2019, 11, 23-33.	1.0	5
71	A multiparametric [18F]FDG PET/MRI diagnostic model including imaging biomarkers of the tumor and contralateral healthy breast tissue aids breast cancer diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1878-1888.	6.4	9
72	Magnetic Resonance Imaging of the Breast in Surgical Planning. , 2019, , 71-86.		0

#	Article	IF	CITATIONS
73	Diffusionâ€Weighted MRI of Breast Cancer: Improved Lesion Visibility and Image Quality Using Synthetic bâ€Values. Journal of Magnetic Resonance Imaging, 2019, 50, 1754-1761.	3.4	27
74	Intra- and inter-observer variability in dependence of T1-time correction for common dynamic contrast enhanced MRI parameters in prostate cancer patients. European Journal of Radiology, 2019, 116, 27-33.	2.6	3
75	MRI evaluation of axillary and intramammary lymph nodes in the postoperative period. Breast Journal, 2019, 25, 916-921.	1.0	3
76	Proton MR spectroscopy in the breast: Technical innovations and clinical applications. Journal of Magnetic Resonance Imaging, 2019, 50, 1033-1046.	3.4	39
77	Can we predict lesion detection rates in second-look ultrasound of MRI-detected breast lesions? A systematic analysis. European Journal of Radiology, 2019, 113, 96-100.	2.6	13
78	Diffusionâ€weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer. Journal of Magnetic Resonance Imaging, 2019, 50, 836-846.	3.4	72
79	Sequential [¹⁸ F]FDG-[¹⁸ F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience. Contrast Media and Molecular Imaging, 2019, 2019, 1-9.	0.8	9
80	Differences in degree of lesion enhancement on CEM between ILC and IDC. BJR Open, 2019, 1, 20180046.	0.6	11
81	Histogram Analysis and Visual Heterogeneity of Diffusion-Weighted Imaging with Apparent Diffusion Coefficient Mapping in the Prediction of Molecular Subtypes of Invasive Breast Cancers. Contrast Media and Molecular Imaging, 2019, 2019, 1-9.	0.8	14
82	Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI. Breast Cancer Research, 2019, 21, 136.	5.0	44
83	Quantitative Multiparametric Breast Ultrasound. Investigative Radiology, 2019, 54, 257-264.	6.2	46
84	Abbreviated MRI of the Breast: Does It Provide Value?. Journal of Magnetic Resonance Imaging, 2019, 49, e85-e100.	3.4	107
85	Quantitative in vivo proton MR spectroscopic assessment of lipid metabolism: Value for breast cancer diagnosis and prognosis. Journal of Magnetic Resonance Imaging, 2019, 50, 239-249.	3.4	34
86	Development of a Non-invasive Assessment of Hypoxia and Neovascularization with Magnetic Resonance Imaging in Benign and Malignant Breast Tumors: Initial Results. Molecular Imaging and Biology, 2019, 21, 758-770.	2.6	23
87	Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients. Investigative Radiology, 2019, 54, 110-117.	6.2	185
88	Beyond Breast Density: Radiomic Phenotypes Enhance Assessment of Breast Cancer Risk. Radiology, 2019, 290, 50-51.	7.3	10
89	Multiparametric MRI model with dynamic contrastâ€enhanced and diffusionâ€weighted imaging enables breast cancer diagnosis with high accuracy. Journal of Magnetic Resonance Imaging, 2019, 49, 864-874.	3.4	49
90	Breast lesion detection and characterization with contrastâ€enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T. Journal of Magnetic Resonance Imaging, 2019, 49, 1157-1165.	3.4	12

#	Article	IF	Citations
91	Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast Cancer Research and Treatment, 2019, 174, 279-296.	2.5	179
92	Diagnosis and Staging of Breast Cancer: When and How to Use Mammography, Tomosynthesis, Ultrasound, Contrast-Enhanced Mammography, and Magnetic Resonance Imaging. IDKD Springer Series, 2019, , 155-166.	0.8	24
93	Determining driver nodes in dynamic signed biological networks. , 2019, , .		3
94	Model reduction of structural biological networks by cycle removal., 2019,,.		0
95	Virtual Touch IQ elastography reduces unnecessary breast biopsies by applying quantitative "rule-in― and "rule-out―threshold values. Scientific Reports, 2018, 8, 3583.	3.3	8
96	A Simple Ultrasound Based Classification Algorithm Allows Differentiation of Benign from Malignant Breast Lesions by Using Only Quantitative Parameters. Molecular Imaging and Biology, 2018, 20, 1053-1060.	2.6	7
97	The frequency of missed breast cancers in women participating in a high-risk MRI screening program. Breast Cancer Research and Treatment, 2018, 169, 323-331.	2.5	29
98	Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis. European Radiology, 2018, 28, 2516-2524.	4.5	22
99	Diffusion-Weighted Imaging With Apparent Diffusion Coefficient Mapping for Breast Cancer Detection as a Stand-Alone Parameter. Investigative Radiology, 2018, 53, 587-595.	6.2	130
100	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ⟨sup⟩18⟨ sup⟩Fâ€⟨scp⟩FDG⟨ scp⟩ injection. Medical Physics, 2018, 45, 2179-2185.	3.0	8
101	MRI-based quantification of residual fibroglandular tissue of the breast after conservative mastectomies. European Journal of Radiology, 2018, 104, 1-7.	2.6	25
102	Multiparametric MRI of the breast: A review. Journal of Magnetic Resonance Imaging, 2018, 47, 301-315.	3.4	105
103	Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET. Molecular Imaging and Biology, 2018, 20, 160-169.	2.6	16
104	Background, current role, and potential applications of radiogenomics. Journal of Magnetic Resonance Imaging, 2018, 47, 604-620.	3.4	137
105	A survey by the European Society of Breast Imaging on the utilisation of breast MRI in clinical practice. European Radiology, 2018, 28, 1909-1918.	4.5	85
106	Clinical role of breast MRI now and going forward. Clinical Radiology, 2018, 73, 700-714.	1.1	83
107	Potential of Noncontrast Magnetic Resonance Imaging With Diffusion-Weighted Imaging in Characterization of Breast Lesions. Investigative Radiology, 2018, 53, 229-235.	6.2	81
108	Automated Detection and Segmentation of Nonmass-Enhancing Breast Tumors with Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Contrast Media and Molecular Imaging, 2018, 2018, 1-11.	0.8	14

#	Article	IF	CITATIONS
109	Quantitative Apparent Diffusion Coefficient Derived From Diffusion-Weighted Imaging Has the Potential to Avoid Unnecessary MRI-Guided Biopsies of mpMRI-Detected PI-RADS 4 and 5 Lesions. Investigative Radiology, 2018, 53, 736-741.	6.2	20
110	Density and tailored breast cancer screening: practice and prediction – an overview. Acta Radiologica Open, 2018, 7, 205846011879121.	0.6	8
111	Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and Treatment. Radiology, 2018, 287, 732-747.	7. 3	203
112	Imaging and the completion of the omics paradigm in breast cancer. Der Radiologe, 2018, 58, 7-13.	1.7	14
113	Imaging Phenotypes in Women at High Risk for Breast Cancer on Mammography, Ultrasound, and Magnetic Resonance Imaging Using the Fifth Edition of the Breast Imaging Reporting and Data System. European Journal of Radiology, 2018, 106, 150-159.	2.6	28
114	CommentaryÂACOG Practice Bulletin July 2017: Breast Cancer Risk Assessment andÂScreening in Average-Risk Women. British Journal of Radiology, 2018, 91, 20170907.	2.2	8
115	Breast ultrasound: recommendations for information to women and referring physicians by the European Society of Breast Imaging. Insights Into Imaging, 2018, 9, 449-461.	3.4	95
116	Determining the importance of parameters extracted from multi-parametric MRI in the early prediction of the response to neo-adjuvant chemotherapy in breast cancer. , 2018, , .		1
117	Determining disease evolution driver nodes in dementia networks. , 2018, , .		5
118	Machine learning for accurate differentiation of benign and malignant breast tumors presenting as non-mass enhancement. , 2018 , , .		4
119	Multi-level analysis of spatio-temporal features in non-mass enhancing breast tumors. , 2018, , .		2
120	PET/MRI and Molecular Imaging in Breast Cancer. , 2018, , 83-98.		0
121	Clinical application of Acoustic Radiation Force Impulse Imaging with Virtual Touch IQ in breast ultrasound: diagnostic performance and reproducibility of a new technique. Acta Radiologica, 2017, 58, 140-147.	1.1	28
122	A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions. European Radiology, 2017, 27, 3799-3809.	4.5	59
123	Personalized Medicine, Biomarkers of Risk and Breast MRI. , 2017, , 337-349.		0
124	Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1428-1437.	6.4	74
125	The driving regulators of the connectivity protein network of brain malignancies. , 2017, , .		4
126	Dynamical graph theory networks techniques for the analysis of sparse connectivity networks in dementia. , $2017, \ldots$		6

#	Article	IF	CITATIONS
127	Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2017, 163, 565-571.	2.5	77
128	Accuracy of fully automated, quantitative, volumetric measurement of the amount of fibroglandular breast tissue using MRI: correlation with anthropomorphic breast phantoms. NMR in Biomedicine, 2017, 30, e3705.	2.8	12
129	Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 55-66.	6.4	117
130	MRI in the Assessment of BI-RADS® 4 lesions. Topics in Magnetic Resonance Imaging, 2017, 26, 191-199.	1.2	11
131	Application of BI-RADS Descriptors in Contrast-Enhanced Dual-Energy Mammography: Comparison with MRI. Breast Care, 2017, 12, 212-216.	1.4	37
132	Comparison of screening CEDM and MRI for women at increased risk for breast cancer: A pilot study. European Journal of Radiology, 2017, 97, 37-43.	2.6	98
133	Advanced Imaging for Precision Medicine in Breast Cancer: From Morphology to Function. Breast Care, 2017, 12, 208-210.	1.4	6
134	Automated Semi-Quantitative Analysis of Breast MRI: Potential Imaging Biomarker for the Prediction of Tissue Response to Neoadjuvant Chemotherapy. Breast Care, 2017, 12, 231-236.	1.4	8
135	Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer. Radiotherapy and Oncology, 2017, 125, 420-425.	0.6	25
136	The breast lesion excision system (BLES) under stereotactic guidance cannot be used as a therapeutic tool in the excision of small areas of microcalcifications in the breast. European Journal of Radiology, 2017, 93, 252-257.	2.6	11
137	The potential of multiparametric MRI of the breast. British Journal of Radiology, 2017, 90, 20160715.	2.2	110
138	Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey. European Radiology, 2017, 27, 2737-2743.	4.5	136
139	Diffusion-weighted imaging of breast lesions: Region-of-interest placement and different ADC parameters influence apparent diffusion coefficient values. European Radiology, 2017, 27, 1883-1892.	4.5	82
140	Investigating the prediction value of multiparametric magnetic resonance imaging at 3ÂT in response to neoadjuvant chemotherapy in breast cancer. European Radiology, 2017, 27, 1901-1911.	4.5	59
141	Dynamical Graph Theory Networks Methods for the Analysis of Sparse Functional Connectivity Networks and for Determining Pinning Observability in Brain Networks. Frontiers in Computational Neuroscience, 2017, 11, 87.	2.1	10
142	Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer. PLoS ONE, 2017, 12, e0180790.	2.5	7
143	Multiparametric Imaging: Cutting-Edge Sequences and Techniques Including Diffusion-Weighted Imaging, Magnetic Resonance Spectroscopy, and PET/CT or PET/MRI., 2017,, 283-320.		0
144	Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study. PLoS ONE, 2016, 11, e0155333.	2.5	45

#	Article	IF	Citations
145	Influence of fat-water separation and spatial resolution on automated volumetric MRI measurements of fibroglandular breast tissue . NMR in Biomedicine, 2016, 29, 702-708.	2.8	7
146	Head-to-head comparison of PI-RADS v2 and PI-RADS v1. European Journal of Radiology, 2016, 85, 1125-1131.	2.6	88
147	18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1937-1944.	6.4	53
148	Diagnostic performance of digital breast tomosynthesis with a wide scan angle compared to full-field digital mammography for the detection and characterization of microcalcifications. European Journal of Radiology, 2016, 85, 2161-2168.	2.6	38
149	Proteomic data analysis of glioma cancer stem-cell lines based on novel nonlinear dimensional data reduction techniques. Proceedings of SPIE, 2016, , .	0.8	0
150	Computer-aided diagnosis of diagnostically challenging lesions in breast MRI: a comparison between a radiomics and a feature-selective approach. , 2016 , , .		0
151	Diffusionâ€weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy. NMR in Biomedicine, 2016, 29, 1445-1453.	2.8	46
152	Quantitative Assessment of Breast Parenchymal Uptake on ¹⁸ F-FDG PET/CT: Correlation with Age, Background Parenchymal Enhancement, and Amount of Fibroglandular Tissue on MRI. Journal of Nuclear Medicine, 2016, 57, 1518-1522.	5.0	19
153	Inter- and intra-observer agreement of BI-RADS-based subjective visual estimation of amount of fibroglandular breast tissue with magnetic resonance imaging: comparison to automated quantitative assessment. European Radiology, 2016, 26, 3917-3922.	4.5	22
154	The Impact That Number of Analyzed Metastatic Breast Cancer Lesions Has on Response Assessment by ¹⁸ F-FDG PET/CT Using PERCIST. Journal of Nuclear Medicine, 2016, 57, 1102-1104.	5.0	26
155	Quantitative Sodium MR Imaging at 7 T: Initial Results and Comparison with Diffusion-weighted Imaging in Patients with Breast Tumors. Radiology, 2016, 280, 39-48.	7.3	69
156	MR-guided vacuum-assisted breast biopsy of MRI-only lesions: a single center experience. European Radiology, 2016, 26, 3908-3916.	4.5	39
157	A simple scoring system for breast MRI interpretation: does it compensate for reader experience?. European Radiology, 2016, 26, 2529-2537.	4.5	62
158	Diffusion-weighted imaging of breast tumours at 3ÂTesla and 7ÂTesla: a comparison. European Radiology, 2016, 26, 1466-1473.	4.5	18
159	Contrast-enhanced dual energy mammography with a novel anode/filter combination and artifact reduction: a feasibility study. European Radiology, 2016, 26, 1575-1581.	4.5	19
160	Multiparametric MRI of the prostate at 3ÂT: limited value of 3D 1H-MR spectroscopy as a fourth parameter. World Journal of Urology, 2016, 34, 649-656.	2.2	16
161	PIK3CA mutational status and correlation with tumor glycolysis imaged with [18F]FDG PET/CT in early primary ER+ / HER2- breast cancer patients: A feasibility study Journal of Clinical Oncology, 2016, 34, e12050-e12050.	1.6	0
162	Visual exploratory analysis of integrated chromosome 19 proteomic data derived from glioma cancer stem-cell lines based on novel nonlinear dimensional data reduction techniques. Proceedings of SPIE, 2015, , .	0.8	0

#	Article	IF	CITATIONS
163	Breast MRI: EUSOBI recommendations for women's information. European Radiology, 2015, 25, 3669-3678.	4.5	330
164	Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy. Radiotherapy and Oncology, 2015, 117, 509-514.	0.6	25
165	Bilateral Diffusion-weighted MR Imaging of Breast Tumors with Submillimeter Resolution Using Readout-segmented Echo-planar Imaging at 7 T. Radiology, 2015, 274, 74-84.	7.3	58
166	Multiparametric MR Imaging with High-Resolution Dynamic Contrast-enhanced and Diffusion-weighted Imaging at 7 T Improves the Assessment of Breast Tumors: A Feasibility Study. Radiology, 2015, 276, 360-370.	7. 3	44
167	Dynamical complex network theory applied to the therapeutics of brain malignancies. Proceedings of SPIE, 2015, , .	0.8	0
168	Dixon imaging-based partial volume correction improves quantification of choline detected by breast 3D-MRSI. European Radiology, 2015, 25, 830-836.	4.5	2
169	Introduction of an Automated User–Independent Quantitative Volumetric Magnetic Resonance Imaging Breast Density Measurement System Using the Dixon Sequence. Investigative Radiology, 2015, 50, 73-80.	6.2	30
170	Quantitative Apparent Diffusion Coefficient as a Noninvasive Imaging Biomarker for the Differentiation of Invasive Breast Cancer and Ductal Carcinoma In Situ. Investigative Radiology, 2015, 50, 95-100.	6.2	87
171	Diagnostic accuracy of 18F-FDG PET/CT compared with that of contrast-enhanced MRI of the breast at 3 T. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 1656-1665.	6.4	22
172	The role of positron emission tomography in breast cancer: a short review. Memo - Magazine of European Medical Oncology, 2015, 8, 130-135.	0.5	1
173	Activity of T-DM1 in Her2-positive breast cancer brain metastases. Clinical and Experimental Metastasis, 2015, 32, 729-737.	3.3	103
174	PET/MRI in cervical cancer: Insights into tumor biology Journal of Clinical Oncology, 2015, 33, 5597-5597.	1.6	1
175	Magnetic Resonance Imaging-Guided Prostate Biopsy: Institutional Analysis and Systematic Review. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2014, 186, 501-507.	1.3	18
176	Evaluation of Diffusion-Weighted MRI for Pretherapeutic Assessment and Staging of Lymphoma: Results of a Prospective Study in 140 Patients. Clinical Cancer Research, 2014, 20, 2984-2993.	7.0	100
177	Dynamic Contrast-Enhanced Magnetic Resonance Imaging of Breast Tumors at 3 and 7 T. Investigative Radiology, 2014, 49, 354-362.	6.2	27
178	Improved Diagnostic Accuracy With Multiparametric Magnetic Resonance Imaging of the Breast Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Diffusion-Weighted Imaging, and 3-Dimensional Proton Magnetic Resonance Spectroscopic Imaging. Investigative Radiology, 2014, 49, 421-430.	6.2	107
179	Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study. Clinical Cancer Research, 2014, 20, 3540-3549.	7.0	82
180	Molecular imaging for the characterization of breast tumors. Expert Review of Anticancer Therapy, 2014, 14, 711-722.	2.4	7

#	Article	IF	CITATIONS
181	Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7ÂT. European Radiology, 2014, 24, 913-920.	4.5	49
182	MRI-only lesions: application of diffusion-weighted imaging obviates unnecessary MR-guided breast biopsies. European Radiology, 2014, 24, 1204-1210.	4.5	87
183	Fat saturation in dynamic breast MRI at 3ÂTesla: is the Dixon technique superior to spectral fat saturation? A visual grading characteristics study. European Radiology, 2014, 24, 2213-2219.	4.5	38
184	Rate of Malignancy in MRI-Detected Probably Benign (BI-RADS 3) Lesions. American Journal of Roentgenology, 2014, 202, 684-689.	2.2	32
185	T-DM1 in HER2-positive breast cancer brain metastases (BM) Journal of Clinical Oncology, 2014, 32, 650-650.	1.6	1
186	Effect of multiparametric MRI of the breast on diagnostic accuracy Journal of Clinical Oncology, 2014, 32, 11009-11009.	1.6	0
187	Combined contrast-enhanced magnetic resonance and diffusion-weighted imaging reading adapted to the "Breast Imaging Reporting and Data System―for multiparametric 3-T imaging of breast lesions. European Radiology, 2013, 23, 1791-1802.	4.5	106
188	Teleradiology with uncompressed digital mammograms: Clinical assessment. European Journal of Radiology, 2013, 82, 412-416.	2.6	5
189	Factors Influencing Agreement Between Core Needle Biopsy and Surgical Resection Specimens Regarding KI67 Labeling Index – Results of a Retrospective Analysis. Annals of Oncology, 2013, 24, iii13.	1.2	0
190	Molecular subtyping of breast cancer using dedicated breast PET-CT Journal of Clinical Oncology, 2013, 31, e22090-e22090.	1.6	0
191	Readout-segmented Echo-planar Imaging Improves the Diagnostic Performance of Diffusion-weighted MR Breast Examinations at 3.0 T. Radiology, 2012, 263, 64-76.	7.3	180
192	Molecular imaging of cancer: MR spectroscopy and beyond. European Journal of Radiology, 2012, 81, 566-577.	2.6	65
193	High resolution MRI of the breast at 3AT : which BI-RADS \hat{A} ® descriptors are most strongly associated with the diagnosis of breast cancer?. European Radiology, 2012, 22, 322-330.	4.5	62
194	Conspicuity of breast cancer according to histopathological type and breast density when imaged by full-field digital mammography compared with screen-film mammography. European Radiology, 2011, 21, 18-25.	4. 5	8
195	The impact of digital mammography on screening a young cohort of women for breast cancer in an urban specialist breast unit. European Radiology, 2011, 21, 676-682.	4.5	19
196	Three-dimensional Proton MR Spectroscopic Imaging at 3 T for the Differentiation of Benign and Malignant Breast Lesions. Radiology, 2011, 261, 752-761.	7.3	61
197	Molecular Imaging in Breast Cancer – Potential Future Aspects. Breast Care, 2011, 6, 110-119.	1.4	12
198	Detection of degenerative cartilage disease: comparison of high-resolution morphological MR and quantitative T2 mapping at 3.0 Tesla. Osteoarthritis and Cartilage, 2010, 18, 1211-1217.	1.3	100

#	Article	IF	CITATIONS
199	Delayed gadoliniumâ€enhanced MRI of cartilage in the ankle at 3 T: Feasibility and preliminary results after matrixâ€associated autologous chondrocyte implantation. Journal of Magnetic Resonance Imaging, 2010, 31, 732-739.	3.4	41
200	Textureâ€based classification of focal liver lesions on MRI at 3.0 Tesla: A feasibility study in cysts and hemangiomas. Journal of Magnetic Resonance Imaging, 2010, 32, 352-359.	3.4	80
201	Comparison of 5-megapixel cathode ray tube monitors and 5-megapixel liquid crystal monitors for soft-copy reading in full-field digital mammography. European Journal of Radiology, 2010, 76, 68-72.	2.6	6
202	Diffusion-weighted MR for Differentiation of Breast Lesions at 3.0 T: How Does Selection of Diffusion Protocols Affect Diagnosis?. Radiology, 2009, 253, 341-351.	7.3	262
203	Dedicated multi-detector CT of the esophagus: spectrum of diseases. Abdominal Imaging, 2009, 34, 3-18.	2.0	66
204	Kinematic biomechanical assessment of human articular cartilage transplants in the knee using 3-T MRI: an in vivo reproducibility study. European Radiology, 2009, 19, 1246-1252.	4.5	14
205	Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of malignant and benign breast lesions. European Radiology, 2009, 19, 2349-2356.	4.5	63
206	A Combined High Temporal and High Spatial Resolution 3 Tesla MR Imaging Protocol for the Assessment of Breast Lesions. Investigative Radiology, 2009, 44, 553-558.	6.2	104
207	T1(Gd) Gives Comparable Information as Delta T1 Relaxation Rate in dGEMRIC Evaluation of Cartilage Repair Tissue. Investigative Radiology, 2009, 44, 598-602.	6.2	48
208	High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology, 2008, 50, 9-16.	2.2	33
209	Differentiating normal hyaline cartilage from post-surgical repair tissue using fast gradient echo imaging in delayed gadolinium-enhanced MRI (dGEMRIC) at 3 Tesla. European Radiology, 2008, 18, 1251-1259.	4.5	90
210	Metabolic changes in the normal ageing brain: Consistent findings from short and long echo time proton spectroscopy. European Journal of Radiology, 2008, 68, 320-327.	2.6	76
211	Longitudinal Evaluation of Cartilage Composition of Matrix-Associated Autologous Chondrocyte Transplants with 3-T Delayed Gadolinium-Enhanced MRI of Cartilage. American Journal of Roentgenology, 2008, 191, 1391-1396.	2.2	21
212	Proton magnetic resonance spectroscopy in pituitary macroadenomas: preliminary results. Journal of Neurosurgery, 2008, 109, 306-312.	1.6	26
213	Reference Data for In Vivo Magnetic Resonance Imaging Properties of Meniscoids in the Cervical Zygapophyseal Joints. Spine, 2008, 33, E778-E783.	2.0	16
214	High-Resolution Contrast-Enhanced, Susceptibility-Weighted MR Imaging at 3T in Patients with Brain Tumors: Correlation with Positron-Emission Tomography and Histopathologic Findings. American Journal of Neuroradiology, 2007, 28, 1280-1286.	2.4	63
215	Proton Magnetic Resonance Spectroscopic Imaging in the Border Zone of Gliomas. Investigative Radiology, 2007, 42, 218-223.	6.2	46
216	Improved Preoperative Evaluation of Cerebral Cavernomas by High-Field, High-Resolution Susceptibility-Weighted Magnetic Resonance Imaging at 3 Tesla. Investigative Radiology, 2007, 42, 346-351.	6.2	39

#	Article	IF	CITATIONS
217	Comparison of fMRI coregistration results between human experts and software solutions in patients and healthy subjects. European Radiology, 2007, 17, 1634-1643.	4.5	18
218	The prevalence of lumbar facet joint edema in patients with low back pain. Skeletal Radiology, 2007, 36, 755-760.	2.0	58
219	Matrix-based autologous chondrocyte implantation for cartilage repair with Hyalograft®C: Two-year follow-up by magnetic resonance imaging. European Journal of Radiology, 2006, 57, 9-15.	2.6	87
220	Contrast-Enhanced, High-Resolution, Susceptibility-Weighted Magnetic Resonance Imaging of the Brain. Investigative Radiology, 2006, 41, 249-255.	6.2	42
221	Are cerebral cavernomas truly nonenhancing lesions and thereby distinguishable from arteriovenous malformations?. Magnetic Resonance Imaging, 2006, 24, 631-637.	1.8	35
222	The optimal use of contrast agents at high field MRI. European Radiology, 2006, 16, 1280-1287.	4.5	75
223	Matrix-based autologous chondrocyte implantation for cartilage repair: noninvasive monitoring by high-resolution magnetic resonance imaging. Magnetic Resonance Imaging, 2005, 23, 779-787.	1.8	131
224	The value of high-field MRI (3T) in the assessment of sellar lesions. European Journal of Radiology, 2005, 54, 327-334.	2.6	79
225	Application of three-tesla magnetic resonance imaging for diagnosis and surgery of sellar lesions. Journal of Neurosurgery, 2004, 100, 278-286.	1.6	105
226	MR Contrast Agent at High-Field MRI (3 Tesla). Topics in Magnetic Resonance Imaging, 2003, 14, 365-375.	1.2	50
227	Effect of Contrast Dose and Field Strength in the Magnetic Resonance Detection of Brain Metastases. Investigative Radiology, 2003, 38, 415-422.	6.2	75
228	MRI-Based Machine Learning Radiomics Can Predict HER2 Expression Level and Pathologic Response after Neoadjuvant Therapy in HER2 Overexpressing Breast Cancer. SSRN Electronic Journal, 0, , .	0.4	1